Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
MSLP > SEC Filings for MSLP > Form 8-K on 30-Aug-2013All Recent SEC Filings

Show all filings for MUSCLEPHARM CORP



Entry into a Material Definitive Agreement, Financial Statements and Exhibits


On August 26, 2013, MusclePharm Corporation (the "Company") entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") with BioZone Pharmaceuticals, Inc. (the "Seller") pursuant to which the Company bought (i) $2,000,000 of a 10% secured convertible promissory notes (the "Note") due one year from the date of issuance (the "Maturity Date") and (ii) a warrant (the "Warrant") to purchase 10,000,000 shares of the Seller's common stock, at an exercise price of $0.40 per share, for $2,000,000.

The entire principal amount and any accrued and unpaid interest on the Note is due and payable in cash on the Maturity Date. The Note bears interest at the rate of 10% per annum. The Note is convertible into shares of the Seller's common stock at an initial conversion price of $0.20 per share, subject to adjustment. The Seller may prepay any outstanding amount due under the Note, in whole or in part, prior to the Maturity Date. The Note is subject to certain "Events of Defaults" which could cause all amounts due and owing thereunder to become immediately due and payable. Among other things, the Seller's failure to pay any accrued but unpaid interest when due, the failure to perform any obligation under the Transaction Documents (as defined below) or a determination that any representation or warranty made by the Seller in connection with the Transaction Documents shall prove to have been incorrect in any material respect shall constitute an Event of Default under the Transaction Documents.

The Warrant is immediately exercisable and expires ten years after the date of issuance. The Warrant has an initial exercise price of $0.40 per share. The Warrant is exercisable in cash or by way of a "cashless exercise" while a registration statement covering the shares of the Seller's common stock issuable upon exercise of the Warrant or an exemption from registration is not available.

The Company is prohibited from effecting a conversion of the Note or exercise of the Warrant to the extent that as a result of such conversion or exercise, the Company would beneficially own more than 4.99% (subject to waiver) in the aggregate of the issued and outstanding shares of the Seller's common stock, calculated immediately after giving effect to the issuance of shares of common stock upon conversion of the Note or exercise of the Warrant, as the case may be.

In connection with the sale of the Note and the Warrant, the Company, the Seller and the collateral agent for other secured creditors of the Seller (including the Seller's Chairman, Roberto Prego-Novo) agreed to enter into a Security Agreement Letter (the "Security Agreement Letter" and, collectively with the Securities Purchase Agreement, the Note and the Warrant, the "Transaction Documents") pursuant to which all of the Seller's obligations under the Note are secured by a perfected security interest in the name of the Company in all of the tangible and intangible assets of the Seller, including all of its ownership interest in its subsidiaries, pari pasu, with the previous secured creditors, all of which is subordinated to the accounts receivable lender to the Seller. Further, pursuant to the Security Agreement Letter, the Company, the collateral agent and the prior secured creditors agreed to further subordinate the granted security interest to a security interest previously granted to another investor in the Seller.

The Seller has granted the Company "piggy-back" registration rights with respect to the shares of common stock underlying the Note and the shares of common stock underlying the Warrant for a period of twelve (12) months from the date of closing.

The foregoing descriptions of the Securities Purchase Agreement, the Note, the Warrant and the Security Agreement are not complete and are qualified in their entirety by reference to Exhibits 10.1, 10.2, 10.3 and 10.4, annexed hereto.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.   Description

10.1          Securities Purchase Agreement
10.2          Form of Note
10.3          Form of Warrant
10.4          Security Agreement Letter

  Add MSLP to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for MSLP - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.